| Name | Title | Contact Details |
|---|---|---|
Tracy Piner |
Director, Digital Marketing | Profile |
Fabio Patino |
Vice President of IT and Chief Information Security Officer | Profile |
Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
Vivex Biomedical, Inc. is a biomaterials developer headquartered in Marietta, Georgia. Vivex is focused on creating treatment options and creative solutions to advance clinical, surgical and therapeutic patient care. We have made significant progress in a short time, bringing together the brightest minds in the scientific community and from the orthopaedic and material science industries. Through our focus on continued innovation in next-generation biomaterials, Vivex is creating a new standard in patient care and delivering groundbreaking health products to meet the needs of a diverse, rapidly expanding market.
At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife
Accelerated Genetics is a Baraboo, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.